Sparsentan Alternatives Compared
Sparsentan | Tarpeyo | Cyclophosphamide |
|
---|
Sparsentan | Tarpeyo (budesonide) | Cyclophosphamide |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Primary Immunoglobulin A Nephropathy. sparsentan may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Primary Immunoglobulin A Nephropathy. Tarpeyo may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Acute Lymphocytic Leukemia, Bladder Cancer, Brain Tumor, Acute Nonlymphocytic Leukemia, Breast Cancer, Bullous Pemphigoid, Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia... View more |
Related suggestions Primary Immunoglobulin A Nephropathy
|
|||||||||||||||
More about Sparsentan | More about Tarpeyo (budesonide) | More about Cyclophosphamide | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Cyclophosphamide has an average rating of 8.6 out of 10 from a total of 12 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: sparsentan side effects in more detail. |
See also: Tarpeyo side effects in more detail. |
See also: cyclophosphamide side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Tarpeyo prices |
View all cyclophosphamide prices |
||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Filspari | Other budesonide brands include: Entocort EC, Eohilia, Pulmicort Flexhaler, Pulmicort Respules, Uceris |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
9.6 hours |
2.8 hours |
6.5 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 576 drugs are known to interact with sparsentan:
|
A total of 511 drugs are known to interact with Tarpeyo:
|
A total of 379 drugs are known to interact with cyclophosphamide:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
February 17, 2023 |
December 15, 2021 |
November 16, 1959 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.